In this video interview with PharmTech Europe, Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, discussed the CMC challenges with GLP-1 and oral peptides during his attendance at CPHI Milan.
Dr. Lewis talked about the chemistry, manufacturing, and control (CMC) challenges encountered during the development of glucagon-like peptide 1 (GLP-1) and oral peptides.
Watch the full video and read the article on PharmTech Europe.